47.69
price up icon1.32%   0.62
after-market アフターアワーズ: 47.36 -0.33 -0.69%
loading
前日終値:
$47.07
開ける:
$46.98
24時間の取引高:
343.85K
Relative Volume:
0.87
時価総額:
$3.06B
収益:
$88.55M
当期純損益:
$-157.85M
株価収益率:
-17.28
EPS:
-2.76
ネットキャッシュフロー:
$-137.92M
1週間 パフォーマンス:
-1.65%
1か月 パフォーマンス:
+10.75%
6か月 パフォーマンス:
+27.51%
1年 パフォーマンス:
+234.20%
1日の値動き範囲:
Value
$46.34
$48.88
1週間の範囲:
Value
$42.62
$48.88
52週間の値動き範囲:
Value
$13.85
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1182)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
181
Name
Twitter
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
08:13 AM

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey

08:13 AM
pulisher
07:29 AM

Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times

07:29 AM
pulisher
03:54 AM

Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

03:54 AM
pulisher
Nov 04, 2024

UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat

Nov 04, 2024
pulisher
Nov 04, 2024

Immunology to take front seat at Kymera - The Pharma Letter

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India

Nov 04, 2024
pulisher
Nov 04, 2024

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St

Nov 04, 2024
pulisher
Nov 04, 2024

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

(KYMR) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024
pulisher
Nov 02, 2024

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024
pulisher
Nov 02, 2024

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN

Nov 02, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

The Latest Analyst Ratings For Kymera Therapeutics - Benzinga

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK

Nov 01, 2024
pulisher
Nov 01, 2024

B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks

Nov 01, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownTime to Sell? - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - StockTitan

Oct 31, 2024
pulisher
Oct 31, 2024

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com

Oct 31, 2024
pulisher
Oct 30, 2024

Preview: Kymera Therapeutics's Earnings - Benzinga

Oct 30, 2024
pulisher
Oct 30, 2024

Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga

Oct 30, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN

Oct 24, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat

Oct 24, 2024
pulisher
Oct 24, 2024

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan

Oct 24, 2024
pulisher
Oct 23, 2024

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com

Oct 23, 2024
pulisher
Oct 23, 2024

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times

Oct 23, 2024
pulisher
Oct 17, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World

Oct 17, 2024
pulisher
Oct 16, 2024

Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Oct 15, 2024
pulisher
Oct 14, 2024

SG Americas Securities LLC Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

Kymera Therapeutics (NASDAQ:KYMR) & Novozymes A/S (OTCMKTS:NVZMY) Critical Comparison - Defense World

Oct 13, 2024
pulisher
Oct 12, 2024

How To Trade (KYMR) - Stock Traders Daily

Oct 12, 2024
pulisher
Oct 10, 2024

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance - Yahoo Finance

Oct 10, 2024
pulisher
Oct 09, 2024

Kymera advances novel STAT6 degrader into clinical trials - Investing.com

Oct 09, 2024
pulisher
Oct 09, 2024

Kymera Therapeutics' Application for KT-621 Gets FDA Clearance - Marketscreener.com

Oct 09, 2024
pulisher
Oct 09, 2024

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Kymera advances novel STAT6 degrader into clinical trials By Investing.com - Investing.com UK

Oct 09, 2024
pulisher
Oct 08, 2024

The Manufacturers Life Insurance Company Raises Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

Healthcare of Ontario Pension Plan Trust Fund Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Oct 07, 2024
pulisher
Oct 07, 2024

Dimensional Fund Advisors LP Buys 53,176 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors - Seeking Alpha

Oct 06, 2024
pulisher
Oct 05, 2024

Algert Global LLC Purchases 4,622 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Oct 05, 2024
pulisher
Oct 04, 2024

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by ProShare Advisors LLC - Defense World

Oct 04, 2024

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
大文字化:     |  ボリューム (24 時間):